文献速递血栓与止血造血干细胞移植与细胞治疗

异基因造血干细胞移植后血栓性血小板减少性紫癜:罕见但致命的并发症

Thrombotic thrombocytopenic purpura following allogeneic hematopoietic stem cell transplantation: a rare but fatal complication.
PubMed 文献 · J Thromb Haemost · 2025-12-11

该回顾性巢式病例对照研究分析了26例异基因造血干细胞移植后TTP患者,并与高危移植相关TMA患者匹配对照。TTP患者中枢神经系统和胃肠道受累比例更高,总生存率显著更低(26.9% vs 48.7%),诊断时年龄>40岁是60天总生存的独立预测因素。

要点

  • 移植后TTP虽罕见,但可与高危TA-TMA鉴别,且预后更差。
  • TTP患者中枢神经系统和胃肠道受累比例显著高于高危TA-TMA。
  • 诊断时年龄>40岁是TTP患者60天总生存的独立预测因素。

核心结论

  • 异基因造血干细胞移植后TTP虽罕见,但可与TA-TMA相鉴别,且与更差的预后相关。

研究设计与样本

  • 回顾性队列研究,采用巢式病例对照方法,按移植时间为每例TTP患者匹配3例高危TA-TMA患者作为对照。
  • 共纳入26例异基因造血干细胞移植后TTP患者。

主要发现

  • TTP诊断时年龄>40岁是60天总生存的独立预测因素。

临床怎么用

  • 移植后出现TMA表现时,应鉴别TTP与TA-TMA,因两者预后不同。
  • TTP患者中枢神经系统和胃肠道受累更突出,可作为鉴别参考。
  • 诊断TTP时年龄>40岁提示60天生存预后更差。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombotic microangiopathy (TMA) is a common and potentially fatal complication following allogeneic hematopoietic stem cell transplantation (allo-HSCT). Thrombotic thrombocytopenic purpura (TTP), a distinct form of TMA caused by severe deficiency of plasma ADAMTS-13 activity, has been reported to be rare in the posttransplant population. OBJECTIVES: To investigate the clinical features and outcomes of TTP after allo-HSCT. METHODS: This retrospective cohort study used a nested case‒control approach. For each patient with TTP, 3 patients with high-risk transplant-associated TMA (TA-TMA) were matched as controls according to the time of transplantation. RESULTS: A total of 26 patients with TTP were identified and included in the cohort. Compared with patients with high-risk TA-TMA, patients with TTP had greater proportions of central nervous system (50.0% vs 19.2%, P = .002) and gastrointestinal tract involvement (65.4% vs 32.1%, P = .003), with central nervous system dysfunction occurring later (8.0 days vs -1.0 days since the diagnosis of TTP, P = .008). Patients with TTP had a significantly lower overall survival rate than those with high-risk TA-TMA (26.9% vs 48.7%, log-rank P = .026). Age >40 years at the time of TTP diagnosis was identified as an independent predictor of 60-day overall survival. CONCLUSION: TTP occurring in the setting of HSCT is rare but can be differentiated from TA-TMA and is associated with a worse prognosis.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Li Z, Zhao P, Fu H, et al. Thrombotic thrombocytopenic purpura following allogeneic hematopoietic stem cell transplantation: a rare but fatal complication. J Thromb Haemost. 2025. PMID: 41390106. doi:10.1016/j.jtha.2025.11.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。